Clear cell carcinoma is a clinically and pathologically distinct entity among surface epithelial ovarian neoplasms, recognized for its resistance to standard platinum-based chemotherapy at advanced stage disease and poor prognosis. Despite advances in our understanding of the biology of other surface epithelial ovarian neoplasms, very little is known about the molecular genetic mechanisms that are involved in clear cell tumorigenesis. Early mitotic inhibitor-1 (Emi1) protein is a key cell cycle regulator, that promotes S-phase and mitotic entry by inhibiting the anaphase promoting complex. In cell culture systems, overexpression of Emi1 leads to tetraploidy and genomic instability, especially in the absence of normal p53 function. We investigated Emi1 protein expression in ovarian neoplasms using a tissue microarray constructed from 339 primary ovarian surface epithelial (serous, endometrioid, clear cell, and mucinous) and peritoneal (serous) neoplasms, stromal and mesenchymal tumors, germ cell tumors, and normal ovarian tissue. Significant overexpression of Emi1 protein was present in 82% (27/33) clear cell carcinoma, including one borderline tumor in a diffuse, granular cytoplasmic and perinuclear staining pattern, independent of patient age, presence of ovarian and/or pelvic endometriosis, and FIGO stage. In contrast, only 10% (17/177) primary ovarian and primary peritoneal serous carcinomas, 0% (0/10) mucinous carcinomas, and 19% (6/32) endometrioid carcinomas exhibited significant Emi1 protein overexpression. Accumulation of Emi1 protein was not linked to Ki-67 labeling index, but was directly correlated with cyclin E and inversely correlated with ER in clear cell carcinoma (Po0.001). Compared to the serous surface epithelial subtype, which comprises the majority of ovarian carcinomas, clear cell carcinoma is less common (less than 15%) and is frequently associated with ovarian and/or pelvic endometriosis, paraneoplastic hypercalcemia, and thromboembolic complications. Unlike its serous counterpart, clear cell carcinoma frequently presents at low FIGO stage and exhibits a comparatively poor response to conventional platinum-based chemotherapy at high-stage disease. The pathologic features of clear cell carcinoma are distinctive. Clear cell carcinoma, originally thought to be of mesonephric origin by Schiller (hence the old term 'mesonephroma'), is noted for its characteristic hobnail cells, clear cytoplasm, and mixed glandular, solid and tubulocystic architecture. In recent years, a dualistic model for the development and progression of ovarian cancer has been proposed, based in part on the presence or absence of recognizable precursor lesions.
Ovarian clear cell carcinoma is a highly aggressive and often chemoresistant surface epithelial neoplasm associated with a poor 5-year survival. 1 Compared to the serous surface epithelial subtype, which comprises the majority of ovarian carcinomas, clear cell carcinoma is less common (less than 15%) and is frequently associated with ovarian and/or pelvic endometriosis, paraneoplastic hypercalcemia, and thromboembolic complications. Unlike its serous counterpart, clear cell carcinoma frequently presents at low FIGO stage and exhibits a comparatively poor response to conventional platinum-based chemotherapy at high-stage disease. The pathologic features of clear cell carcinoma are distinctive. Clear cell carcinoma, originally thought to be of mesonephric origin by Schiller (hence the old term 'mesonephroma'), is noted for its characteristic hobnail cells, clear cytoplasm, and mixed glandular, solid and tubulocystic architecture. In recent years, a dualistic model for the development and progression of ovarian cancer has been proposed, based in part on the presence or absence of recognizable precursor lesions. 2 The evidence for this model is drawn primarily by comparing molecular genetic and gene expression data in serous borderline/low-grade carcinomas and their high-grade counterparts. Similar tumorigenic models for mucinous and endometrioid neoplasms have also been proposed. 2 However, no such model exists for clear cell carcinoma and the pathobiology of this neoplasm continues to be poorly understood. 3 Disruption of cell cycle checkpoints is a common underlying mechanism in human carcinogenesis leading to an increased rate of proliferation and/or decreased death of abnormal cells. 4 In particular, misregulation of the p53 network is found in a significant proportion of human carcinomas, either linked to inactivating mutations of p53 or through alterations in genes whose products interact directly or indirectly with p53. 5 p53 inactivating mutations, which occur commonly in serous ovarian cancer, are conspicuously absent in clear cell carcinoma, and although overexpression of MDM2, a negative regulator of the p53 protein may be operative in some of these tumors, the potential role of other key cell cycle regulators in clear cell tumorigenesis has not been well defined. [6] [7] [8] [9] Early mitotic inhibitor-1 (Emi1), a recently characterized E2F transcriptional target, is a key cell cycle regulator that is required for accumulation of mitotic cyclins and other critical cell cycle regulators during S and G2 phases. [10] [11] [12] [13] Emi1 functions as a pseudo-substrate inhibitor of the anaphase promoting complex/cyclosome (APC/ C). [14] [15] [16] Upregulation of Emi1 mRNA has been found in a variety of malignant tumors compared to matched normal and benign tumor tissue. Indeed, Emi1 overexpression causes mitotic catastrophe and genomic instability through APC/C misregulation, and thus potentially contributes to tumorigenesis. 10 In a large-scale screen of a variety of human neoplasms examining protein expression of Emi1 and tumorigenic APC/C substrates, overexpression of Emi1 was specifically implicated in clear cell carcinoma. 17 To further evaluate the possible role of Emi1-mediated cell cycle misregulation in clear cell carcinoma, we examined the expression of Emi1 protein in a series of benign, borderline and malignant ovarian epithelial tumors and normal ovarian tissues using a tissue microarray platform and selected whole tissue sections. Our results support a potential link between Emi1 overexpression and tumorigenesis in clear cell carcinoma.
Materials and methods

Tissue Selection and Tissue Microarray Construction
Tissue microarrays were constructed from paraffinembedded tissue of primary ovarian and extra-ovarian tumors (n ¼ 339) as well as normal ovarian tissue using a manual tissue arrayer (Beecher Instruments, Silver Spring, MD, USA) as described previously. 18 19 Primary vs recurrent tumors and tumors with mixed histology were noted. In addition, representative tissue sections of selected ovarian tumors as well as normal ovarian tissue from premenopausal and postmenopausal women with no history of ovarian cancer (n ¼ 5) were obtained from the archives. The premenopausal ovary tissues were selected to represent follicular, luteal and post-luteal phases.
Immunohistochemistry
Serial sections of 4 mm each were cut from the array blocks and deparaffinized by routine techniques. Each TMA was placed in 200 ml of target retrieval solution, pH 6.0 (Envision Plus Detection Kit, Dako) for 20 min at 1001C. After cooling for 20 min, slides were quenched with 3% H 2 O 2 for 5 min before incubating with primary antibody using the Dako Autostainer. The primary antibodies used were as follows: affinity-purified rabbit anti-human-Emi1 polyclonal antibody (1:500 dilution); 10 anti-estrogen receptor monoclonal antibody (clone 15d, 1:50 dilution, Dako); anti-cyclin E (clone 13A3, 1:40 dilution, Novocastra), and anti-Ki-67 (clone IVAK-2, 1:100 dilution, Dako). Labeling was performed with the Dako EnVision þ System according to the manufacturer's protocol. Positive controls were included for each antibody. Negative controls were performed by replacing primary antibody with rabbit control serum. Specificity of Emi1 antibodies was previously demonstrated through prior incubation of the antiserum with purified Emi1 protein. 17 Two of the investigators (IG and TAL) scored epithelial cytoplasmic and/or nuclear staining for Emi1 using a three-tiered scale, although only cytoplasmic staining was considered positive. Because Emi1 expression exhibited a variable pattern of staining intensity with less variation in overall Emi1 in clear cell carcinoma I Gü tgemann et al percentage of positive cells, scoring was based on intensity of staining. Immunostaining in o5% of tumor cells was considered negative and immunostaining in 45% tumor cells was further scored as low level or high level, depending on the intensity of expression. Immunohistochemical staining for ER, cyclin E, and Ki-67, all of which exhibited uniform intensity of expression from case to case, was scored as negative (o5% of cell nuclei staining positively), weakly positive (5-30% of nuclei positive), or strongly positive (430% nuclei positive).
Only appropriate subcellular localization of detectable signal was considered for assessment of percentage staining (cytoplasmic expression for Emi1 and nuclear expression for ER, Ki-67, and cyclin E). Cases in which immunoreactivity could not be assessed for technical reasons (eg, failure of the tissue cores to stick to the slide or no representative tissue in either core) were excluded from analysis. In cases where there was a discrepancy in the staining result recorded for the duplicate cores, the higher score was accepted for that case (eg, for a case with negative staining in one core and low-level staining in the other, the case was considered to show low level expression).
FIGO Stage and Follow-Up
Patient age, FIGO stage of disease, and clinical follow-up were obtained for all tumor cases by review of the hospital charts.
Statistical Analysis
Statistical analysis was performed using Microstat statistical software (Ecosoft, Indianapolis, IN, USA). Fisher's exact test, and where indicated, the trend test, a modification of the w 2 test for ordered categorical data, was performed. The two-sided level of significance was set at Po0.05. Similarly, 95% confidence intervals and the Spearman's correlation coefficient were calculated.
Results
Emi1 Protein Expression in Ovarian Neoplasms
To understand the role of Emi1 protein in ovarian tumors, we used immunohistochemical analysis to examine Emi1 protein in normal ovary and ovarian tumors. Normal ovarian stromal tissue demonstrated no significant Emi1 expression, except in tissues containing post-antral, involuting or recently ruptured follicles. The granulosa cell layer of these Graafian follicles (Figure 1 In contrast, low-or high-level Emi1 expression was present in a significant proportion of ovarian surface epithelial tumors (43%). Emi1 expression in these tumors exhibited a diffuse, cytoplasmic and perinuclear granular staining pattern that was particularly prominent in the clear cell tumors (Figure 4) , whereas the majority of serous, endometrioid, and mucinous neoplasms either exhibited no expression or only low levels of Emi1 expression (Table 1) . Clear cell tumors exhibited high-level Emi1 expression ( Figure 5 ) in 27 of 33 or 82% of clear cell carcinoma (including one borderline tumor), whereas high-level Emi1 protein expression was present only in 10% (17/177) primary ovarian and primary peritoneal serous carcinomas, 0/10 mucinous carcinomas, and 19% (6/32) endometrioid carcinomas. High-level Emi1 expression was more common in serous tumors of low malignant potential and low-grade serous carcinomas than in the high-grade serous cancers (17 vs 10%). Three of the six endometrioid cancers (all grade 2, two high stage) with high Emi1 expression were associated with endometriosis, one with mixed endometrioid and clear cell histology. Emi1 overexpression was also seen in 1/5 endometrioid tumors of low malignant potential and 3/4 endometrioisis unassociated with carcinoma, two of which were atypical ( Figure 6) . 20, 21 Two germ cell tumors (one yolk sac tumor and one dysgerminoma) and one (of six) adult granulosa cell tumor demonstrated strong Emi1 expression; all other sex cord neoplasms studied were negative for Emi1. Altogether, taking low-and high-level expression, 
Emi1 Protein Accumulation in Relation to ER Expression in Clear Cell Carcinoma
Since the loss of estrogen receptor in breast and ovarian tumors may contribute to increased and unregulated expression of cell cycle regulators, we also evaluated the link between ER and Emi1 in ovarian tumors. Emi1 expression was inversely correlated with ER protein expression in clear cell carcinoma (Figure 4) , with only 3/33 clear cell carcinomas exhibiting low levels of ER expression (two of the three were Emi1-negative, of which one was mixed serous and clear cell carcinoma). In contrast, more than half of the serous carcinomas (91/177; 52%), 52% of endometrioid carcinomas, 10% of mucinous carcinomas and 77% of serous tumors of low malignant potential expressed the ER protein (Table 1) . Comparison between all five groups was statistically significant (Po0.001). Thus, ER-negative cases were most frequent among clear cell carcinomas and mucinous carcinomas and ERpositive cases were most frequent among the serous tumors of low malignant potential. No statistically significant correlation between Emi1 and ER expression was found in any group but clear cell carcinoma, where an inverse correlation of Emi1 and ER expression was demonstrated (Spearman's coefficient À0.454, P ¼ 0.008).
Emi1 Protein Accumulation in Relation to Cyclin E and Ki-67 Labeling Index in Clear Cell Carcinoma
In addition to ER status, cyclin E levels have been clearly implicated in the prognosis of breast cancer 22 and potentially, ovarian cancer. 23, 24 To test this link, we evaluated the relationship between expression of cyclin E and Emi1 in ovarian tumors. High-cyclin E expression was present in 29/33 (88%) CCC, 64% serous carcinomas, 26% endometrioid carcinomas and 0% mucinous carcinomas. Pairwise comparison between the histologic subtypes showed significant overexpression of cyclin E in the clear cell carcinoma group compared to the other subtypes (Table 1) , and this was directly correlated with Emi1 overexpression in clear cell carcinoma (Po0.0001). Overexpression of Emi1 occurred in association with elevated cyclin E in all but one clear cell carcinoma (Figure 4) .
To determine whether Emi1 expression in the tumor tissue was reflective of a generalized increase in tumor cell proliferation, Emi1 expression was 
Emi1 in clear cell carcinoma
I Gü tgemann et al correlated with Ki-67 labeling in the tissue arrays and in representative full tissue sections. Although Ki-67 expression was highly variable among the tumors, levels of expression were generally lower in the clear cell carcinomas than in all serous carcinomas combined and no correlation between Emi1 expression and clear cell carcinoma tumor cell proliferation, as assessed by either Ki-67 labeling or mitotic index was found (data not shown).
Emi1 Expression in Putative Precursor Lesions and in Early and Late Stage Clear Cell Carcinoma
Emi1 expression was absent in 4/4 examples of assessable ovarian endometriosis, while 2/2 Emi þ with available follow-up), but the numbers of cases were too few to draw statistical inferences.
Discussion
Clear cell carcinoma is a clinically and pathologically distinct entity among surface epithelial ovarian neoplasms, recognized for resistance to standard platinum-based chemotherapy at advanced stage disease and poor prognosis. The accumulated evidence from a variety of disciplines indicates that clear cell carcinoma also has several distinct cytogenetic, molecular genetic, and gene expression alterations when compared to other more common surface epithelial neoplasms. 8, [25] [26] [27] [28] Not surprisingly, some of the differentially expressed genes found on mRNA expression studies of ovarian carcinoma fall into a proliferation cluster or cluster with genes encoding proteins involved in cell cycle progression. 26 Misregulation of the G1/S transition in the cell cycle is a fundamental component of the cellular transformation process and G1/S regulatory defects have been reported in a variety of human malignancies.
Here, we studied the expression of Emi1, a recently described key cell cycle regulator that is essential for normal regulation of the APC/C, in a series of normal, benign, and malignant ovarian tissues using a tissue microarray platform. We found that Emi1 protein, although expressed in a variety of malignant ovarian tumors, was significantly overexpressed in clear cell carcinomas with 85% exhibiting at least some degree of Emi1 protein expression, and most at high levels (82% of all clear cell carcinomas). Emi1 protein accumulation in clear cell carcinoma was directly associated with upregulation of cyclin E and, with one exception, was found only when cyclin E was overexpressed, but was not related to a generalized increased proliferative activity. The next highest frequency of Emi1 overexpression in the ovarian surface epithelial tumor subsets occurred in endometrioid carcinomas (19%). We also found low levels of Emi1 expression in two cases of atypical endometriosis, and in borderline tumors of each subtype. Taken together, these findings provide strong circumstantial evidence for the role of Emi1-mediated misregulation of the APC/C pathway in clear cell carcinoma. Moreover, misregulation of the pathway is likely to be an early event, because complete absence of Emi1 in clear cell carcinoma appears to occur only in high stage or recurrent disease. Misregulation of the APC/C pathway has also been reported in colon and breast cancers and although APC/C substrates have been implicated in ovarian carcinogenesis, specific upregulation of a key cell cycle regulator of the APC/C in clear cell carcinoma has not been previously documented. 17, 26, [29] [30] [31] [32] Upregulation of Emi1, which also occurs at the transcriptional level, has been reported in other neoplasms in association with cyclin E overexpression. 10, 17 Coexpression of these two proteins is consistent with Emi1 being an E2F target, since cyclin E/cdk2 phosphorylates pRb and promotes the transcription of E2F target genes. 10 Overexpression of cyclin-dependent kinase or cyclin E may lead to activated E2F and overexpression of the E2F-dependent APC/C regulator Emi1. 10 Alternatively, loss of upstream regulators such as pRb or cdk inhibitors with resultant misregulation and accumulation of Emi1 protein may account for the observed protein overexpression in this study. In clear cell carcinoma, overexpression of Emi1 may contribute to aggressive tumor growth by driving cell cycle progression at an increased rate and/or inducing genomic instability. 33 Tetraploidy, an important intermediary step in tumor progression, has been reported in a significant proportion of ovarian clear cell carcinoma and mitotic errors with centrosome overduplication and abnormal spindle formation have been linked to Emi1 accumulation in the absence of normal p53 function. 7, 12, [33] [34] [35] In this model, additional p53 pathway destabilizing mechanisms, such as MDM2 alterations, would presumably occur, since p53 mutations are unusual in clear cell carcinoma. 10, 36 Recently, Shih and Kurman 2 have proposed a dualistic tumor progression model for ovarian carcinogenesis, based on the presence or absence of precursor lesions. Type I tumors, represented by low-grade serous carcinoma, mucinous carcinoma, endometrioid carcinoma, and clear cell carcinoma arise in a stepwise manner from well-recognized precursor lesions, whereas Type II tumors appear to arise de novo from surface epithelium or inclusions. 37 The development of ovarian endometrioid and clear cell neoplasia in association with endometriosis is well established and models of Emi1 in clear cell carcinoma I Gütgemann et al tumorigenesis involving acquisition of a series of genetic alterations in foci of endometriosis have been proposed. 2, 6, 30, [38] [39] [40] However, the pathways for the development of clear cell carcinoma and endometrioid carcinoma differ in several important respects. First, tumors with predominantly endometrioid differentiation tend to retain ER whereas those with predominantly clear cell differentiation lose ER, analogous to poor prognosis ER-negative breast cancers. Second, alterations in the Wnt/b-catenin signaling pathway have been consistently identified in ovarian endometrioid tumors with and without endometriosis, but no such alterations have been consistently identified in clear cell carcinoma. [41] [42] [43] Third, the proliferative index of endometrioid tumors is significantly higher than in clear cell carcinoma, even though the latter tumor tends to behave in a more aggressive fashion when high stage. 25, 30, 44 Our data, combined with those of others, provide strong evidence for the role of Emi1-mediated misregulation of the APC/C pathway in ovarian clear cell carcinoma and provide, for the first time, a tenable tumor progression model for these tumors. This tumor progression model, based on Emi1-driven misregulation of the APC/C pathway, does not exclude the role of other molecular defects that have been identified in ovarian clear cell carcinoma, and likely acts in synergy with some of these other key events to enhance tumor formation ( Figure 7 ). 45 Although not specifically examined in this study, Emi1 also appears to be overexpressed in some ovarian germ cell and stromal tumors. In this series, dysgerminoma and yolk sac tumors exhibited high levels of Emi1 expression, whereas all immature and mature teratomas showed no Emi1 expression. Emi1 and/or structurally similar Emi1-related proteins are considered to be integral to the maintenance of oocyte arrest at metaphase of meiosis II by their actions on the APC/C complex. 11 In the normal ovary, Emi1 is overexpressed at low levels in ovarian granulosa cells in post-antral follicles and in the ovarian stroma during follicle rupture and atresia, but not in the oocytes or stroma of primordial follicles (Figure 1) . The relationship, if any between Emi1 during normal follicular development and its overexpression in germ cell tumors, such as yolk sac tumors (and rarely, granulosa cell tumors) as well as in germinomas 17 is unclear and the numbers of cases studied are too small to draw statistical inferences, but possible activation of the APC/C pathway in these tumors deserves further study.
In summary, ovarian clear cell carcinoma exhibits high-level Emi1 protein overexpression in the vast majority of clear cell carcinoma and appears to be lost only in recurrent and poor prognosis high-stage disease. Emi1 accumulation is associated with elevated cyclin E and is unrelated to proliferative activity, consistent with an Emi1-mediated misregulation of the APC/C pathway. 33 The role of Emi1 and the APC/C pathway in clear cell carcinoma is supported by low-to-intermediate level Emi1 protein expression in atypical endometriosis and high expression in some endometrioid carcinomas, including tumors with mixed endometrioid and clear cell histology. These findings represent a potentially important insight into the molecular pathway underlying clear cell carcinogenesis and provide a possible novel cell cycle regulatory model for future studies aimed at elucidating the pathogenesis and mechanisms of chemoresistance of these neoplasms.
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